1. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19;Unoh;J Med Chem,2022
2. Press release on March 5, 2024. Xocova® (ensitrelvir fumaric acid) obtained standard approval in Japan for the treatment of SARS-CoV-2 infection. Available at: https://www.shionogi.com/global/en/news/2024/03/20240305.html. Accessed April 16, 2024.
3. Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults;Shimizu;Antimicrob Agents Chemother,2022
4. Evaluation of the drug-drug interaction potential of ensitrelvir fumaric acid with cytochrome P450 3A substrates in healthy Japanese adults;Shimizu;Clin Drug Investig,2023
5. Evaluation of drug-drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and a clinical study;Shimizu;J Clin Pharmacol,2023